Section Edited by Marcela V. Maus, MD, PhD
Immune cell therapies and cell engineering approaches, new targets, novel functionalities, clinical trial results, correlative studies in patients who have received cell-based therapies, novel engineering strategies (molecular switches, conditional expression, logic gating), gene-edited cells to knock out or knock in novel functions, synthetic gene circuits. Includes pre-clinical animal modeling (small and large) and clinical trials.
EphA3 CAR T cells are effective against glioblastoma in preclinical modelsPaulo Martins, Rochelle C J D’Souza, Niclas Skarne, Lea Lekieffre, Shane Horsefield, Madusha Ranjankumar, Xiang Li, Thuy T Le, Fiona Smith, Corey Smith, Jacqueline Burrows, Bryan W Day, Rajiv Khanna
7 August 2024
Preclinical activity of allogeneic SLAMF7-specific CAR T-cells (UCARTCS1) in multiple myelomaCharlotte L B M Korst, Chloe O’Neill, Wassilis S C Bruins, Meliha Cosovic, Inoka Twickler, Christie P M Verkleij, Diane Le Clerre, Maria Themeli, Isabelle Chion-Sotinel, Sonja Zweegman, Roman Galetto, Tuna Mutis, Niels W C J van de Donk
25 July 2024
Targeting a STING agonist to perivascular macrophages in prostate tumors delays resistance to androgen deprivation therapyHaider Al-janabi, Katy Moyes, Richard Allen, Matthew Fisher, Mateus Crespo, Bora Gurel, Pasquale Rescigno, Johann de Bono, Harry Nunns, Christopher Bailey, Anna Junker-Jensen, Munitta Muthana, Wayne A Phillips, Helen B Pearson, Mary-Ellen TaplinSee the full list of authors
25 July 2024
Enhanced IL-15-mediated NK cell activation and proliferation by an ADAM17 function-blocking antibody involves CD16A, CD137, and accessory cellsAnders W Matson, Rob Hullsiek, Kate J Dixon, Sam Wang, Anders J Lindstedt, Ryan R Friess, Shee Kwan Phung, Tanya S Freedman, Martin Felices, Emily N Truckenbrod, Jianming Wu, Jeffrey S Miller, Bruce Walcheck
24 July 2024
Directing B7-H3 chimeric antigen receptor T cell homing through IL-8 induces potent antitumor activity against pediatric sarcomaJessica A Lake, Elena Woods, Eric Hoffmeyer, Kristin L Schaller, Joselyn Cruz-Cruz, Joseph Fernandez, Dejene Tufa, Benjamin Kooiman, Spencer C Hall, Dallas Jones, Masanori Hayashi, Michael R Verneris
23 July 2024
rhIL-7-hyFc, a long-acting interleukin-7, improves efficacy of CAR-T cell therapy in solid tumorsDan Li, Tianyuzhou Liang, Laura E Hutchins, Alexandra A Wolfarth, Sara Ferrando-Martinez, Byung Ha Lee, Mitchell Ho
23 July 2024
First-in-human dose escalation trial to evaluate the clinical safety and efficacy of an anti-MAGEA1 autologous TCR-transgenic T cell therapy in relapsed and refractory solid tumorsMartin Wermke, Tobias A W Holderried, Jason John Luke, Van K Morris, Winfried H Alsdorf, Katrin Wetzko, Borje S Andersson, Ignacio I Wistuba, Edwin R Parra, Mohammad B Hossain, Sandra Grund-Gröschke, Katrin Aslan, Arun Satelli, Anantha Marisetty, Swapna SatamSee the full list of authors
22 July 2024
Proteomic and phenotypic characteristics of memory-like natural killer cells for cancer immunotherapyHelena Arellano-Ballestero, Agnieszka Zubiak, Chris Dally, Kim Orchard, Aljawharah Alrubayyi, Xenia Charalambous, Melina Michael, Robert Torrance, Trinity Eales, Kushal Das, Maxine G. B. Tran, May Sabry, Dimitra Peppa, Mark W. Lowdell
20 July 2024
Generation of non-genetically modified, CAR-like, NK cellsLoïs Coënon, Emilie Rigal, Hortense Courot, Caroline Multrier, Sara Zemiti, Jennifer Lambour, Martine Pugnière, Marion de Toledo, Guillaume Bossis, Guillaume Cartron, Bruno Robert, Pierre Martineau, Bénédicte Fauvel, Jessy Presumey, Martin Villalba
18 July 2024
Off-the-shelf CAR-NK cells targeting immunogenic cell death marker ERp57 execute robust antitumor activity and have a synergistic effect with ICD inducer oxaliplatinLiuhai Zheng, Huifang Wang, Jihao Zhou, Guangwei Shi, Jingbo Ma, Yuke Jiang, Zhiyu Dong, Jiexuan Li, Yuan-Qiao He, Dinglan Wu, Jichao Sun, Chengchao Xu, Zhijie Li, Jigang Wang
4 July 2024